Global Gene Therapy for CNS Disorders Market 2019-2023
About this market
The increase in special drug designations is one of the key factors anticipated to witness continuous growth in the forthcoming years. Vendors are receiving special drug designations for their novel gene therapies to help in receiving quicker approval. Some market players are even offering the orphan drug designation with various tax benefits on their clinical researches. As a result, the rising number of special drug designations from the regulatory bodies will drive the gene therapy for CNS disorders market growth in the forthcoming years. Technavio’s analysts have predicted that the gene therapy for CNS disorders market will register a CAGR of nearly 27% by 2023.
Market Overview
Increase in special drug designations
One of the growth drivers of the global gene therapy for CNS disorders market is the increase in special drug designations. The increasing number of special drug designations from the regulatory bodies is expected to result in the quicker approval of gene therapy programs, which drives the growth of the market.
Uneven distribution of technology
One of the challenges in the growth of the global gene therapy for CNS disorders market is the Uneven distribution of technology. The lack of focus of major vendors on developing gene therapy for CNS disorders are expected to hinder the market growth during the forecast period.
For the detailed list of factors that will drive and challenge the growth of the gene therapy for CNS disorders market during 019-2023, view our report.
Competitive Landscape
The market appears to be highly concentrated with the presence of a few market players. Vendors in the market are developing advanced technologies that help in manufacturing gene therapies with superior efficacy for the treatment of various CNS indications. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Press Release
Technavio Announces the Publication of its Research Report – Global Gene Therapy for CNS Disorders Market 2019-2023
Technavio recognizes the following companies as the key players in the global gene therapy for CNS disorders market: Biogen, bluebird bio, Inc., Novartis AG, Pfizer Inc., and Voyager Therapeutics.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is the changing perception related to ethical issues.”
According to the report, one of the major drivers for this market is the advent of novel technologies.
Further, the report states that one of the major factors hindering the growth of this market is the uneven distribution of technology.
Companies Mentioned
Biogen
bluebird bio, Inc.
Novartis AG
Pfizer Inc.
Voyager Therapeutics
- Executive summary
- Scope of the report
- Preface
- Currency conversion rates for US$
- Market landscape
- Market ecosystem
- Table Global pharmaceuticals market
- Table Segments of global pharmaceuticals market
- Market characteristics
- Table Market characteristics
- Market segmentation analysis
- Table Market segments
- Market ecosystem
- Market sizing
- Market definition
- Table Market definition - Inclusions and exclusions checklist
- Market sizing 2018
- Table Market size 2018
- Market size and forecast 2018-2023
- Table Global market: Size and forecast 2018-2023 ($ millions)
- Table Global market: Year-over-year growth 2019-2023 (%)
- Market definition
- Five forces analysis
- Table Five forces analysis 2018
- Table Five forces analysis 2023
- Bargaining power of buyers
- Table Bargaining power of buyers
- Bargaining power of suppliers
- Table Bargaining power of suppliers
- Threat of new entrants
- Table Threat of new entrants
- Threat of substitutes
- Table Threat of substitutes
- Threat of rivalry
- Table Threat of rivalry
- Market condition
- Table Market condition - Five forces 2018
- Pipeline
- Table Global gene therapy for CNS disorders market pipeline: Overview
- Table Global gene therapy for CNS disorders market pipeline: Snapshot
- Market segmentation by indication
- Table Indication - Market share 2018-2023 (%)
- Comparison by indication
- Table Comparison by indication
- SMA - Market size and forecast 2018-2023
- Table SMA - Market size and forecast 2018-2023 ($ millions)
- Table SMA - Year-over-year growth 2019-2023 (%)
- Others - Market size and forecast 2018-2023
- Table Others - Market size and forecast 2018-2023 ($ millions)
- Table Others - Year-over-year growth 2019-2023 (%)
- Market opportunity by indication
- Table Market opportunity by indication
- Customer landscape
- Table Customer landscape
- Geographic landscape
- Geographic segmentation
- Table Market share by geography 2018-2023 (%)
- Geographic comparison
- Table Geographic comparison
- North America - Market size and forecast 2018-2023
- Table North America - Market size and forecast 2018-2023 ($ millions)
- Table North America - Year-over-year growth 2019-2023 (%)
- Table Top 3 countries in North America
- Europe - Market size and forecast 2018-2023
- Table Europe - Market size and forecast 2018-2023 ($ millions)
- Table Europe - Year-over-year growth 2019-2023 (%)
- Table Top 3 countries in Europe
- Asia - Market size and forecast 2018-2023
- Table Asia - Market size and forecast 2018-2023 ($ millions)
- Table Asia - Year-over-year growth 2019-2023 (%)
- Table Top 3 countries in Asia
- ROW - Market size and forecast 2018-2023
- Table ROW - Market size and forecast 2018-2023 ($ millions)
- Table ROW - Year-over-year growth 2019-2023 (%)
- Table Top 3 countries in ROW
- Key leading countries
- Table Key leading countries
- Market opportunity
- Table Market opportunity
- Geographic segmentation
- Decision framework
- Drivers and challenges
- Market drivers
- Market challenges
- Table Impact of drivers and challenges
- Market trends
- Vendor landscape
- Overview
- Table Vendor landscape
- Landscape disruption
- Table Landscape disruption
- Competitive scenario
- Overview
- Vendor analysis
- Vendors covered
- Table Vendors covered
- Vendor classification
- Table Vendor classification
- Market positioning of vendors
- Table Market positioning of vendors
- Biogen
- Table Biogen - Vendor overview
- Table Biogen - Business segments
- Table Biogen - Organizational developments
- Table Biogen - Geographic focus
- Table Biogen - Key offerings
- Table Biogen - Key customers
- bluebird bio, Inc.
- Table bluebird bio, Inc. - Vendor overview
- Table bluebird bio, Inc. - Product segments
- Table bluebird bio, Inc. - Organizational developments
- Table bluebird bio, Inc. - Key offerings
- Table bluebird bio, Inc. - Key customers
- Novartis AG
- Table Novartis AG - Vendor overview
- Table Novartis AG - Business segments
- Table Novartis AG - Organizational developments
- Table Novartis AG - Geographic focus
- Table Novartis AG - Segment focus
- Table Novartis AG - Key offerings
- Table Novartis AG - Key customers
- Pfizer Inc.
- Table Pfizer Inc. - Vendor overview
- Table Pfizer Inc. - Business segments
- Table Pfizer Inc. - Organizational developments
- Table Pfizer Inc. - Geographic focus
- Table Pfizer Inc. - Segment focus
- Table Pfizer Inc. - Key offerings
- Table Pfizer Inc. - Key customers
- Voyager Therapeutics
- Table Voyager Therapeutics - Vendor overview
- Table Voyager Therapeutics - Business segments
- Table Voyager Therapeutics - Organizational developments
- Table Voyager Therapeutics - Key offerings
- Table Voyager Therapeutics - Key customers
- Vendors covered
- Appendix
- Research methodology
- Table Validation techniques employed for market sizing
- List of abbreviations
- Research methodology
- Explore Technavio
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook